Fortitude Family Office LLC Has $618,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fortitude Family Office LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 51.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,727 shares of the company's stock after selling 3,963 shares during the quarter. Fortitude Family Office LLC's holdings in Johnson & Johnson were worth $618,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at about $38,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.2%

Johnson & Johnson stock traded up $0.24 during mid-day trading on Friday, reaching $156.90. The company's stock had a trading volume of 6,587,488 shares, compared to its average volume of 7,947,693. The business's 50 day simple moving average is $153.69 and its 200 day simple moving average is $153.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $377.52 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.